La Jolla Riquent NDA Planned For Year-End; Will Seek Accelerated Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
La Jolla Pharmaceuticals will pursue accelerated approval for its systemic lupus erythematosus agent Riquent (formerly LJP 394).
You may also be interested in...
Riquent "Approvable" For Lupus; FDA Says Ongoing Study Could Be Enough
La Jolla Pharmaceuticals hopes running a parallel study alongside the ongoing confirmatory trial for its lupus agent Riquent will satisfy the requirements set out in FDA’s Oct. 14 "approvable" letter.
FDA Lupus Trial Design Guidance Will Go To Advisory Committee In Fall
FDA is planning to present its draft guidance on lupus clinical trial design at a meeting of the Arthritis Advisory Committee this fall.
FDA Lupus Trial Design Guidance Will Go To Advisory Committee In Fall
FDA is planning to present its draft guidance on lupus clinical trial design at a meeting of the Arthritis Advisory Committee this fall.